Attention, chocolate lovers: You may not be able to help yourselves. Swiss and British scientists have linked the widespread love of chocolate to a chemical "signature" that may be programmed into our metabolic systems.
Read more health news
Combo Therapy Fights AIDS-Linked Lymphoma
|
MONDAY, Feb. 27 (HealthDay News) -- A combination of chemotherapy and aggressive HIV therapy significantly improved survival rates for some HIV-positive patients also battling lymphoma, German researchers report. Lymphomas are cancers of the immune system''s white blood cells. The study included 72 HIV patients with AIDS-related lymphoma treated with a multi-drug chemotherapy called CHOP (cylcophosphamide, doxorubicin, vincristine, and prednisone) and HIV-suppressing, highly active retroviral therapy (HAART). As reported in the April 1 issue of CANCER, this combo improved survival rates for HIV/lymphoma patients without severely impairing their immune systems. Survival rates were comparable to non-HIV lymphoma patients treated with CHOP, according to a team led by Dr. Rudolf Weiss, of the Specialist Practice for Hematology, Oncology and Infectious Diseases, Bremen. The study found that 79 percent of standard-risk AIDS-related lymphoma patients achieved complete lymphoma remission, and more than 50 percent were alive after 47 months. Forty percent of these patients reported moderate drug toxicity. Among high-risk patients -- those with impaired immune systems -- 29 percent achieved complete remission and median survival was 7.2 months, the researchers noted. Sixty-nine percent of these patients reported moderate toxicity. "The present study showed that our risk-adapted strategy for concomitant administration of HAART and CHOP is effective and safe," the German team concluded. More information The U.S. National Cancer Institute has more about treatment for AIDS-related lymphoma.
Last Updated: Feb. 27, 2006 |